Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amicus Therapeutics

6.17
+0.03000.49%
Post-market: 6.170.00000.00%18:41 EDT
Volume:3.86M
Turnover:23.59M
Market Cap:1.90B
PE:-64.19
High:6.19
Open:6.13
Low:6.00
Close:6.14
Loading ...

Amicus Therapeutics Inc Outlook Gaap Net Income Positive During H2 2025

THOMSON REUTERS
·
19 Feb

Amicus Therapeutics 2025 Guidance: Expects Total Revenue Growth Of 17%-24%, Gross Margin In Mid 80% And GAAP Net Income Positive In Second-Half

Benzinga
·
19 Feb

Amicus Therapeutics Q4 2024 Adj. EPS $0.09 Beats $0.01 Estimate, Sales $149.706M Beat $148.012M Estimate

Benzinga
·
19 Feb

BRIEF-Amicus Therapeutics Q4 Net Income USD 14.7 Million

Reuters
·
19 Feb

Amicus Therapeutics Q4 Net Income USD 14.7 Million

THOMSON REUTERS
·
19 Feb

Amicus Therapeutics Q4 EPS USD 0.05

THOMSON REUTERS
·
19 Feb

Press Release: Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

Dow Jones
·
19 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
18 Feb

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

Zacks
·
17 Feb

Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics

Zacks
·
17 Feb

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
13 Feb

Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks
·
12 Feb

Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

GlobeNewswire
·
10 Feb

Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025

GlobeNewswire
·
03 Feb

Is Amicus Therapeutics (FOLD) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

Insider Monkey
·
21 Jan

Amicus Therapeutics, Inc. (FOLD): The Biotech Stock with Biggest Upside Potential

Insider Monkey
·
18 Jan

Amicus Therapeutics Price Target Maintained With a $21.00/Share by Cantor Fitzgerald

Dow Jones
·
15 Jan

Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook

Zacks
·
14 Jan

Amicus Therapeutics: Strong Revenue Performance and Positive Outlook Justify Buy Rating

TIPRANKS
·
13 Jan

Shareholders in Amicus Therapeutics (NASDAQ:FOLD) have lost 32%, as stock drops 3.0% this past week

Simply Wall St.
·
13 Jan